SCHEMBL6494601

SCHEMBL6494601

CCOC(=O)c1cc(S(C)(=O)=O)nn1-c1ccc(OC)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 1/20 0.55
KMT2A Q03164 2/20 0.53
USP2 O75604 1/20 0.53
HTT P42858 1/20 0.53
FAAH O00519 2/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
POLB P06746 2/20 0.47
TDP1 Q9NUW8 2/20 0.47
APEX1 P27695 1/20 0.47
RECQL P46063 1/20 0.47
CTDSP1 Q9GZU7 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
TP53 P04637 2/20 0.47
ALDH1A1 P00352 2/20 0.46
MAPT P10636 3/20 0.45
CA12 O43570 1/20 0.44
CA9 Q16790 1/20 0.44
KDM4E B2RXH2 1/20 0.44
APP P05067 1/20 0.44
ALOX15 P16050 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6173564 0.88 ALDH1A1 (0.50) PDE4DKMT2AHTTSMN1; SMN2RECQL
SCHEMBL6174372 0.84 PDE4D (0.53) PDE4DKMT2AUSP2HTTFAAH
SCHEMBL1873573 0.84 PDE4D (0.61) PDE4DKMT2AUSP2HTTFAAH
SCHEMBL5645113 0.84 RPA1 (0.48) KMT2AUSP2HTTL3MBTL1TP53
SCHEMBL6176728 0.80 PDE4D (0.56) PDE4DKMT2AUSP2HTTFAAH
SCHEMBL6172590 0.79 PDE4D (0.55) PDE4DKMT2AUSP2HTTFAAH
SCHEMBL6172014 0.78 TP53 (0.59) PDE4DKMT2AUSP2HTTFAAH
SCHEMBL19507069 0.78 CA9 (0.56) PDE4DKMT2ASMN1; SMN2POLBALDH1A1
SCHEMBL6501532 0.77 ALDH1A1 (0.39) KMT2AUSP2HTTSMN1; SMN2POLB
SCHEMBL6449685 0.76 FAAH (0.66) PDE4DKMT2AUSP2HTTFAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6949550-B2 Substituted amino methyl factor Xa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2005-09-27 US disclosed
US-6890934-B2 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-05-10 US disclosed
US-20030212054-A1 Substituted amino methyl factor Xa inhibitors BRISTOL-MYERS SQUIBB COMPANY 2003-11-13 US disclosed
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-09-11 US disclosed
US-6573274-B1 Treatment of the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-06-03 US disclosed
EP-1136492-A1 SULFONAMIDE COMPOUNDS AND USES THEREOF AS MEDICINES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-09-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030212054-A1 Substituted amino methyl factor Xa inhibitors F11, F10, F9 PDE4D 1940/4885KMT2A 179/4885USP2 3850/4885
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines PDE2A, PDE3A, PDE5A PDE4D 15/4885KMT2A 1625/4885USP2 1952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.